Albany Molecular Research (AMRI) Tops Q2 EPS by 4c
Tweet
Share
E-mailGet Alerts AMRI Hot Sheet
Price: $21.74 --0%
Financial Fact:
Cost of contract revenue: 123.49M
Today's EPS Names:
UBAB, LOAN, FITB, More
Financial Fact:
Cost of contract revenue: 123.49M
Today's EPS Names:
UBAB, LOAN, FITB, More
Join SI Premium – FREE
Albany Molecular Research (NASDAQ: AMRI) reported Q2 EPS of $0.22, $0.04 better than the analyst estimate of $0.18. Revenue for the quarter came in at $85.2 million versus the consensus estimate of $85 million.
For earnings history and earnings-related data on Albany Molecular Research (AMRI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- The tech crown switches hands: Apple dethrones Nvidia as $4 trillion king
- Taiwan Semi (TSM) PT Raised to $500 at DA Davidson Following Q2 Earnings, Revenue Beat
- Nolan’s ’The Odyssey’ eyes $200M global debut, benefiting IMAX and theater stocks
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
